| Literature DB >> 35902827 |
Christina Næsborg-Nielsen1, Vicky Wilkinson2, Natalia Mejia-Pacheco2, Scott Carver2.
Abstract
BACKGROUND: Sarcoptes scabiei is one of the most impactful mammalian parasites. There has been much research on immunological and clinical pathological changes associated with S. scabiei parasitism across a range of host species. This rich body of literature is complex, and we seek to bring that complexity together in this study. We first (1) synthesise narrative reviews of immunopathological relationships to S. scabiei infection to construct overarching hypotheses; then (2) undertake a systematic meta-analysis of primary literature on immunological and clinical pathological changes; and lastly (3) contrast our findings from the meta-analysis to our synthesis from narrative reviews.Entities:
Keywords: Immunology; Meta-analysis; Pathology; Sarcoptes scabiei; Sarcoptic mange; Scabies
Mesh:
Substances:
Year: 2022 PMID: 35902827 PMCID: PMC9335973 DOI: 10.1186/s12879-022-07635-5
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.667
Fig. 1Diagrams of the immunopathological cascades arising from Sarcoptes scabiei infection depending on host hypersensitivity response (Type I or IV). Diagram A represents the immunopathological processes as currently proposed in narrative literature reviews of S. scabiei, and diagram B represents the Immunopathological relationships supported by the meta-analysis undertaken in this study. Solid arrow ( →) indicates a stimulation or influence from one parameter to the other, whereas a dashed arrow (– →) indicates a hypothesised link; small up or down triangle next to parameter indicates an increase or decrease; red text indicates missing immunological links considered likely to connect parameters; Parameters in non-bold indicates secreted cytokines or immunoglobulins; *in panel B IV indicates no direct measure of macrophages instead measured by MCP-1; **in panel A IV indicates epidermal cells to include keratinocytes, Langerhans cells and fibroblasts; *** in panel B indicates no direct measure of T cells or B cells however could be included in the measurement of lymphocytes. IL interleukin; IFN-γ Interferon gamma; TNF-α tumour necrosis factor alpha; TGF-ß transforming growth factor beta; CD4+= T helper cells; CD8+ cytotoxic T cells; Ig immunoglobulin; C3 complement 3; MCV mean corpuscular volume; TEC total erythrocyte concentration; PCV packed cell volume; AGP Acid(1)-alpha glycoprotein; SAA serum amyloid A; A:G ratio albumin:globulin ratio; ALT alanine aminotransferase; BUN blood urea nitrogen; MCHC mean corpuscular haemoglobin concentration; MCH mean corpuscular haemoglobin; LPO lipid peroxidation; CAT catalase; GSH:GSSH free glutathione:oxidized glutathione ratio; GGT Gamma-glutamyl transferase. Created in Inkscape
Fig. 2Heatmap illustrating the four host species for which effect sizes were most commonly calculated (dog = 138, human = 76, bare-nosed wombat = 67 and Iberian ibex = 63). The heat reflects the percentage of studies for each category (immunological process) with each category amounting to a total of 100%. Parameters not falling directly into a definitive category, such as ‘Erythrocytic changes or ‘Acute phase proteins’, were included in the category ‘Other’
Effect sizes and 95% confidence intervals (round parentheses) for immunological parameters measured during sarcoptic mange in hosts exhibiting Type I hypersensitivity response
| Response | Ctrl vs affected | Ctrl vs mild | Ctrl vs moderate | Ctrl vs severe |
|---|---|---|---|---|
| Total leukocytes | 4.12 (− 1.50; 9.75) [8] | 0.75 (− 0.22; 1.72) [2] | 0.31 (− 0.76; 1.39) [1] | 2.74 ( |
| Lymphocytes | 0.18 (− 1.24; 1.61) [8] | 0.48 (− 3.12; 4.10) [2] | 16.13 ( | − 0.02 (− 6.96; 6.91) [2] |
| Eosinophils | 3.84 ( | 2.48 ( | 3.84 ( | 2.44 ( |
| Mast cells | – | 2.28 ( | 2.79 ( | 4.18 ( |
| Neutrophils | 3.58 (− 1.01; 8.17) [8] | 1.53 ( | 1.63 ( | 3.01 ( |
| Monocytes | − 0.14 (− 1.03; 0.75) [7] | − 0.08 (− 1.01; 0.83) [1]* | − 0.07 (− 1.07; 0.93) [1] | |
| Basophils | 0.41 (− 0.78; 1.61) [3] | – | – | – |
| Macrophage | – | 1.58 ( | 2.31 ( | 8.17 ( |
| CD4+ | − 0.68 ( | – | – | – |
| MCP-1 | 0.35 (− 0.03; 0.73) [1] | – | – | – |
| MIP-1a | 0.05 (− 0.32; 0.44) [1] | – | – | – |
| IgE | 12.57 (− 8.26; 33.41) [5] | 0.98 ( | 2.43 ( | 5.10 ( |
| IgG | 2.01 ( | – | – | – |
| IgA | − 0.65 (− 1.96; 0.65) [2] | – | – | – |
| IgM | 1.46 ( | – | – | – |
| IL-2 | 2.39 ( | – | – | – |
| IL-4 | 5.04 ( | – | – | – |
| IL-5 | 7.69 ( | – | – | – |
| IL-8 | 43.80 (− 42.10; 129.71) [2] | – | – | – |
| IL-10 | 2.36 ( | – | – | – |
| IL-13 | 3.39 ( | – | – | – |
| IL-17 | 0.05 (− 0.33; 0.44) [1] | – | – | – |
| TNF-α | − 7.26 (− 22.10; 7.57) [2] | – | – | – |
| TGF-β | 9.08 ( | – | – | – |
| IFN-γ | − 0.02 (− 0.41; 0.35) [1] | – | – | – |
| C3 | − 1.98 (− 4.96; 0.99) [2] | – | – | – |
The number of parameters across studies are provided in square parentheses. A dash represents that no data was available in the category for the given parameter. References for each parameter can be found in Additional file 2: S2
Significant effect sizes (confidence intervals not overlapping zero) are highlighted in bold
Ctrl, control; MCP-1, Monocyte Chemoattractant Protein-1; MIP-1a, Macrophage Inflammatory Protein-1; IgE, Immunoglobulin E; IgG, Immunoglobulin G; IgA, Immunoglobulin A; IgM, Immunoglobulin M; IL-2, interleukin-2; IL-4, interleukin-4; IL-5, interleukin-5; IL-8, interleukin-8; IL-10, interleukin-10; IL-13, interleukin-13; IL-17, interleukin-17; TNF-α, tumour necrosis factor alpha; TGF-β, Transforming growth factor beta; IFN-γ, Interferon-gamma; C3, Complement 3
*mild/moderate mange disease grouped together in the original article
Effect sizes and 95% confidence intervals (round parentheses) for immunological parameters measured during sarcoptic mange in hosts exhibiting Type IV hypersensitivity response
| Response | Ctrl vs affected | Ctrl vs mild | Ctrl vs moderate | Ctrl vs severe |
|---|---|---|---|---|
| Leukocytes | 0.63 ( | 1.16 (− 0.11; 2.44) [3] | 1.03 (− 1.14; 3.21) [2] | 4.14 (− 0.28; 8.56) [3] |
| Neutrophils | 0.71 (− 0.04; 1.47) [11] | 0.78 ( | 0.39 (− 0.38; 1.16) [2] | 2.89 (− 0.91; 6.70) [4] |
| Lymphocytes | − 0.21 (− 1.34; 0.92) [8] | 0.41 (− 0.01; 0.83) [4] | 0.14 (− 0.24; 0.52) [3] | 0.96 (− 0.49; 2.42) [4] |
| T cells | 1.32 ( | – | – | – |
| Monocytes | 0.81 ( | 0.41 ( | − 0.07 (− 0.51; 0.66) [1] | 1.76 ( |
| Basophils | 0.37 (− 0.47; 1.22) [4] | – | – | – |
| Eosinophils | 1.16 (− 0.74; 3.07) [8] | 0.76 ( | 0.42 (− 0.03; 0.88) [2] | 0.88 (− 0.83; 2.60) [3] |
| Mast cells | – | 0.71 (− 1.65; 0.21) [1] | 0.44 (− 1.16; 0.27) [1] | 0.43 (− 1.12; 0.26) [1] |
| CD4+ | 5.41 ( | – | – | – |
| CD8+ | 5.23 ( | – | – | – |
| MCP-1 | 5.58 ( | – | – | – |
| IgE | 5.04 (− 4.27; 14.35) [2] | – | – | – |
| IgG | 1.33 ( | 1.73 (− 0.54; 4.00) [3]* | 2.81 ( | |
| IgA | − 0.63 | – | – | – |
| IgM | 1.46 ( | – | – | – |
| IL-1 | 0.00 (− 1.08; 1.08) [5] | – | – | – |
| IL-6 | 1.25 (− 2.04; 4.55) [3] | – | – | – |
| IL-8 | − 0.98 (− 2.23; 0.27) [3] | – | – | – |
| IL-17 | 27.65 ( | – | – | – |
| TNF-α | 0.61 (− 0.70; 1.93) [2] | – | – | |
The number of parameters across studies are provided in square parentheses. A dash represents that no data was available in the category for the given parameter. References for each parameter can be found in Additional file 2: S2
Significant effect sizes (confidence intervals not overlapping zero) are highlighted in bold
Ctrl, control; MCP-1, Monocyte Chemoattractant Protein-1; MMI, macrophage migration inhibitor test; TNF-α, Tumour Necrosis Factor alpha; IL-1, Interleukin-1; IL-5, Interleukin-5; IL-6, Interleukin-6; IL-8, Interleukin-8; IL-17, Interleukin-17; IgG, Immunoglobulin G; IgE, Immunoglobulin E; IgM, Immunoglobulin M; IgA, Immunoglobulin A
*mild/moderate mange disease grouped together in the original article
Effect sizes and 95% confidence interval (CI) for oxidant/antioxidant, acute phase protein, erythrocytic, hepatological and nephrological variables measured for hosts with mange (Type I and IV hypersensitivity)
| Response | Ctrl vs affected | Ctrl vs mild | Ctrl vs moderate | Ctrl vs severe |
|---|---|---|---|---|
| Oxidant/antioxidant status | ||||
| LPO | 5.68 ( | 2.36 ( | 4.23 (− 0.52; 8.99) [2] | 3.05 ( |
| SOD | − 4.22 (− 8.99; 0.55) [4] | − 5.82 (− 14.95; 3.31) [7] | − 12.43 (− 31.24; 6.37) [6] | − 1.44 (− 31.24; 6.37) [4] |
| CAT | − 2.39 (− 6.58; 1.79) [3] | − 1.34 (− 3.73; 1.05) [6] | − 2.38 ( | − 2.48 ( |
| GSH | − 5.46 ( | − 6.56 (− 18.07; 4.94) [5] | − 4.71 (− 9.92; 0.48) [5] | − 3.56 (− 8.35; 1.22) [4] |
| GSH:GSSH | – | 0.10 (− 0.54; 0.75) [1] | − 0.27 (− 0.93; 0.37) [1] | − 0.83 ( |
| TOS | 2.54 ( | 0.02 (− 0.62; 0.67) [1] | 0.18 (− 0.46; 0.83) [1] | 1.64 ( |
| MDA | − 0.12 (− 0.73; 0.48) [1] | 0.41 (− 0.15; 0.97) [2] | 1.10 ( | 1.66 ( |
| Zinc | − 1.03 ( | − 1.79 (− 5.37; 1.77) [2] | − 0.73 ( | − 4.14 ( |
| Copper | − 0.47 ( | − 1.03 (− 2.29; 0.23) [4] | − 3.90 (− 10.13; 2.32) [4] | − 3.12 ( |
| Vitamin C | − 3.52 ( | − 1.58 (− 3.36; 0.19) [3] | − 9.72 (− 26.06; 6.60) [2] | − 13.23 (− 35.14; 8.68) [3] |
| Acute phase protein response | ||||
| Ceruloplasmin | 1.35 ( | – | – | – |
| Haptoglobin | 0.69 (− 0.07; 1.45) [3] | − 0.36 (− 0.78; 0.05) [1]* | 0.52 (− 0.13; 1.18) [1] | |
| Transferrin | 1.87 ( | – | – | – |
| AGP | 0.53 ( | 0.60 ( | 1.14 ( | |
| SAA | 68.14 (− 64.55; 200.84) [2] | 0.77 (− 0.68; 2.23) [2] | 0.64 (− 0.07; 1.36) [1] | 1.89 ( |
| Albumin | − 0.73 ( | 0.45 (− 1.14; 2.05) [7] | − 1.04 ( | − 3.38 |
| Erythrocyte changes | ||||
| Haemoglobin | − 0.86 ( | − 3.07 (− 7.07; 0.92) [6] | − 3.67 (− 8.37; 1.02) [4] | − 3.81 ( |
| RBC | − 1.32 ( | − 0.71 ( | − 1.48 ( | − 2.42 ( |
| Haematocrit | − 1.70 ( | − 1.98 ( | − 3.02 ( | − 4.52 (− 9.24; 0.18) [5] |
| MCV | − 0.27 (− 1.16; 0.61) [5] | − 0.82 ( | − 0.07 (− 0.46; 0.31) [3] | 1.51 ( |
| MCH | 0.17 (− 0.30; 0.65) [3] | − 0.23 (− 1.91; 1.44) [2] | − 0.50 (− 1.78; 0.77) [2] | − 0.06 (− 0.97; 0.85) [1] |
| MCHC | − 0.11 (− 0.59; 0.36) [3] | − 0.53 (− 4.05; 2.97) [2] | − 0.64 (− 2.08; 0.85) [2] | − 1.51 ( |
| Iron | − 1.10 ( | − 1.23 (− 5.20; 2.74) [2] | 0.44 (− 0.64; 1.53) [1] | − 3.69 ( |
| Hepatological and nephrological changes | ||||
| Total protein | − 0.80 (− 1.88; 0.27) [16] | − 0.22 (− 0.51; 0.07) [5] | − 0.33 (− 0.92; 0.26) [3] | − 0.76 (− 1.99; 0.47) [4] |
| Globulin | 0.11 (− 0.57; 0.80) [20] | − 0.17 (− 1.03; 0.67) [1] | 0 (− 1.04; 1.04) [1] | − 0.10 (− 1.15; 0.93) [1] |
| ALT | 1.68 ( | 2.21 (− 2.75; 7.18) [4] | 7.53 (− 7.48; 22.54) [2] | 7.31 (− 6.03; 20.65) [4] |
| GGT | – | 2.95 (− 3.21; 9.11) [2] | 11.29 (− 12.33; 34.92) [2] | 29.02 ( |
| Bilirubin | 0.79 (− 0.12; 1.72) [6] | 0.21 (− 0.40; 0.84) [2]* | 1.62 (− 3.50; 6.75) [2] | |
| BUN | 2.06 (− 0.20; 4.32) [4] | 0.16 (− 0.99; 1.31) [3] | 1.33 ( | 0.83 ( |
| Creatinine | 1.13 (− 0.98; 3.26) [8] | − 2.57 (− 5.81; 0.65) [6] | − 2.15 (− 5.44; 1.13) [5] | − 4.08 (− 12.17; 4.01) [4] |
| BUN:Creatinine | – | 1.09 (− 0.03; 2.22) [1] | 1.87 ( | |
| Urea | 0.33 (− 1.59; 2.25) [4] | − 2.42 (− 5.19; 0.35) [2] | − 11.51 (− 35.59; 12.56) [2] | − 3.07 (− 11.49; 5.34) [2] |
| Urea:Nitrogen | – | – | − 0.59 (− 1.33; 0.14) [1] | 0.70 ( |
The number of parameters across studies are provided in square parentheses. A dash represents that no data was available in the category for the given parameter. References for each parameter can be found in Additional file 2: Appendix
Significant effect sizes (confidence intervals not overlapping zero) are highlighted in bold
Ctrl, control; LPO, Lipid peroxidation; SOD, Superoxide dismutase; CAT, Catalase; GSH, Free glutathione; GSH:GSSH, Free glutathione:oxidized glutathione ratio; TOS, Total oxidative stress; MDA, Malondialdehyde; AGP, Acid(1)-alpha glycoprotein; SAA, Serum amyloid A; RBC, Red blood cell; MCV, Mean corpuscular volume; MCH, Mean corpuscular haemoglobin; MCHC, Mean corpuscular haemoglobin concentration; ALT, Alanine aminotransferase; GGT, Gamma-glutamyl transferase; BUN, Blood urea nitrogen
*mild/moderate mange disease grouped together in the original article
Overarching interpretations of complex immunological and clinical pathology results from this study
| Overall | Meta-analysis shows how fragmented research has been for varying immunological and clinical pathology responses (see Figs. |
|---|---|
| Type I responses | Across papers broadly consistent with expectations from narrative reviews, particularly for eosinophil, mast cell and IgE increases. Antibody response increased (e.g. IgE, IgG and IgM) |
| Type IV responses | Less evidence supporting typical cell-mediated response from narrative reviews. No evidence of lymphocytosis, despite individual increases in lymphocytic cells of differing lineages (CD4+ /CD8+ /T cells). Antibodies IgG and IgM increased; IgA decreased |
| Other response types | Acute phase proteins increased in levels with mange Indication of anaemia of chronic disease associated with mange. Results not as clear as what is described in narrative reviews (Fig. Meta-analysis provides possible evidence of association with hepatocellular damage (GGT, ALT), but research is needed to infer whether function is broadly affected. Some inconsistencies between narrative reviews (Fig. Evidence of shifted oxidant/antioxidant balance toward oxidative stress and indication of potential exacterbated disease development, consistent with what is described in narrative reviews (Fig. |
| Interspecific consensus | Increased neutrophils (both Type I and Type IV) Increased IgE in Type I hypersensitivity responses Increased IgG and monocytes in Type IV hypersensitivity responses Consistent changes (increased or decreased) of oxidant/antioxidant parameters Consistent changes (increased or decreased) in acute phase proteins Erythrocytic parameters such as haemoglobin, haemotocrit, MCHC, RBCs decreased consistently |
| Research directions | Appears to be a general need for studies that more routinely compare results against controls rather than in isolation, and include a more standardised suite of variables No data regarding secondary infections across species, important focus for future studies especially in combination with kidney function Research on microbiomes—potential indicator for reduced protection against pathogenic/harmful microorganisms, leading cause for secondary infections |